Dr. Sarah Streett is the new Clinical Director of Inflammatory Bowel Disease at Stanford. She is highly experienced in treating people with IBD, and is expanding our services to offer multi-disciplinary care and opportunities for clinical research participation. She is a member of the Crohn’s and Colitis Medical Advisory Board and has an interest in developing precision therapy for IBD, and in the role that the microbiome and diet play in pathogenesis.
Dr. Streett has a national leadership role in the American Gastroenterological Association, where she currently serves as Chair of the Practice Management and Economics Committee, as well as Chair of the AGA’s initiatives on Obesity. She also serves on the AGA Women’s Leadership Council, the Clinical Guidelines and Government Affairs Committees, and has served as a special government employee at the FDA, and represented the interests of gastroenterologists and their patients on Capitol Hill.
Dr. Streett believes strongly in a collaborative approach to give patient’s personalized care based on the latest therapies for the treatment of IBD.
- Inflammatory Bowel Disease
Clinical Associate Professor, Medicine - Gastroenterology & Hepatology
Clinical Associate Professor, Stanford University (2015 - Present)
Board Certification: Gastroenterology, American Board of Internal Medicine (1997)
Fellowship:Stanford School of Medicine (1997)
Residency:Stanford School of Medicine (1994)
Internship:Stanford School of Medicine (1992)
Medical Education:Johns Hopkins University School of Medicine (1991) MD
Community and International Work
Crohn's and Colitis Medical Advisory Board
Opportunities for Student Involvement